Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights ...

Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...

Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...

Novo Nordisk stock jumped more than 2% in trading Wednesday after beating Wall Street's profit estimates for the first ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The celebrated actress has lost more than 100Ib after turning to controversial diabetes jab Ozempic - now better known for its impact on tackling obesity ...

Shares in Novo Nordisk were up nearly 12% today ... Lilly's obesity therapy recently outperformed Wegovy in a head-to-head weight loss study, while CagriSema's top-line efficacy was in the ...

We expected miracles—what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

"Tirzepatide is the first investigational medicine to deliver more than 20% weight loss on ... Diabetes. Novo Nordisk's STEP trial programme for once-weekly GLP-1 agonist Wegovy (semaglutide ...

A doctor has issued an warning as to why Ozempic shouldn't be used for weight loss as it does one alarming thing to body.